Health Economic Evaluation & Analysis

Health Economics and Outcomes Research (HEOR)

Health economic evaluation and analyses play a key role in modern healthcare decision-making and market access. NIHE helps clients document and understand the economic value of medicines, medical technologies, treatment procedures, and other healthcare innovations. Our researchers have extensive experience in designing and conducting:

Cost-effectiveness / cost-utility / cost-benefit analyses

Budget impact analyses

Cost-of-illness studies

Other types of health economic analyses

We develop health economic models and analyses tailored to different stages of the evidence and decision-making process – from early economic evaluation and evidence generation to HTA, reimbursement, implementation, and post-launch evaluation.

Clients and collaborators

NIHE has conducted health economic evaluations and analyses for pharmaceutical and medtech companies, public authorities, hospitals, and research institutions. Clients and collaborators include AbbVie, Amgros I/S, CSL Seqirus, Department of Infectious Diseases at Aarhus University Hospital, Exact Sciences, Gilead, Hepatology and Gastroenterology at Aarhus University Hospital, NovoCure, Novo Nordisk, the Danish Health Authority, and the Danish Medicines Agency.

Case examples

Explore selected examples of NIHE’s health economic evaluations, analyses, and peer-reviewed publications.

Health and Economic Impact Modelling

NIHE estimated the potential patient benefits and healthcare cost savings of increased SGLT2 inhibitor uptake in chronic kidney disease management in Denmark.

READ THE ARTICLE →

Cost of Illness

As a part of a Nordic study group, NIHE estimated the epidemiological and economic burden of vaccine-preventable respiratory diseases among older adults in the Nordic countries.

READ THE ARTICLE →

Cost-effectiveness/cost utility analysis

In collaboration with clinical scientists from Copenhagen University Hospital - Rigshospitalet, NIHE has estimated the cost-effectiveness of Venetoclax-based treatment in treatment-naïve fit patients With chronic lymphocytic leukemia without TP53 aberrations.

READ THE ARTICLE →